News

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces ...

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, ...